The KATHERINE trial—which enrolled patients with HER2+ early breast cancer with residual invasive disease at surgery after taxane-based neoadjuvant chemotherapy + trastuzumab-containing HER2 blockade—included 180 patients with cT1c tumours at diagnosis (>1 cm and ≤2 cm) [18]. This evidence concerns the gene ERBB2 and neoplasm.